Farmas USA

OCAT

Voilà:

Treatment of Macular Degeneration Using Embryonic Stem Cell-Derived Retinal Pigment Epithelium: Preliminary Results in Asian Patients

http://www.cell.com/stem-cell-reports/fulltext/S2213-6711%2815%2900105-8

Y aquí se puede descargar el pdf completo:

http://www.cell.com/stem-cell-reports/pdfExtended/S2213-6711%2815%2900105-8

-8,64% THLD ??? 

Demasiado rojo para un dia.  Demasiado incluso para ella.

y NVAX va a tocar la alcista ahi en los 7,77 aprox....

joder, que termine el mes de una puta vez, leñe!

por cierto, no dejo de leer en stocktwits aqui y alla que las hostias que estan dando a las farmas sin ingresos es debido al susto que pego CLDN, que estas situaciones tienen sus consecuencias extendiendose el miedo mas alla de la farma de turno burbujeada frente a espectativas que luego se desvanecen ....

THLD

La bajada es criminal, y el gráfico de hoy pinta seguir así. ¿Quién está vendiendo, minoristas o institucionales?

OCAT

Y el comunicado oficial:

The results of this study conducted by CHA Biotech in Asian patients support the findings published in The Lancet in October 2014 and further underscores our leadership in regenerative ophthalmology,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “The safe treatment of a total of forty two patients across multiple studies with this novel therapeutic approach in geographically distinct patient populations is encouraging. We look forward to the planned initiation of our comprehensive Phase 2 safety study in dry AMD and a pivotal study in SMD, two disabling diseases where there is no cure available today.”

In this study there was no evidence of adverse proliferation, tumorigenic behavior, ectopic tissue formation, or other serious safety issues related to the transplanted cells. Although designed as a safety study, visual acuity improved 9–19 letters in three patients and remained stable (+1 letter) in one patient. Vision was measured using the widely accepted standard for visual acuity testing, the Early Treatment Diabetic Retinopathy Study visual acuity exam.

Robert Lanza, M.D., Chief Scientific Officer of Ocata Therapeutics and co-senior author of the paper, commented, “These results support the potential safety and efficacy of hESC-derived cells in Asian patients and provides further evidence that hESC-derived cells could serve as a potentially safe new source for regenerative medicine.”

http://ir.ocata.com/press-releases/detail/2776

CLDN

Pues las Celedonio van subiendo bien hoy, a ver cómo acaban. Se pusieran hoy a 4 dólares, ché....